Insights

  • Home
  • Insights
  • U.S. Targets Pharma for Anti-Bribery Scrutiny, Jones Day In Print

Share

U.S. Targets Pharma for Anti-Bribery Scrutiny, Jones Day In Print

April 2010 External Publications
You May Also Be Interested In

APRIL 2024 Commentary

New York's LLC Transparency Act: What You Need to Know

April 2024 Alert

SEC Prevails in Novel "Shadow Trading" Insider Trading Trial

APRIL 2024 Commentary

Substantial Strengthening of Australia's Foreign Bribery Laws: Are Your Procedures up to Scratch?

April 2024 Alert

SEC Reaffirms Importance of Self-Reporting and Cooperation, but Benefits Remain Ambiguous

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.